Subsidiary Satsuma Pharmaceuticals Received Us FDA Approval For Acute Migraine Treatment Atzumi (Sts101)

Shin Nippon Biomedical Laboratories

01/05/2025 01:09

May 1 (Reuters) - Shin Nippon Biomedical Laboratories Ltd 2395.T:

SHIN NIPPON BIOMEDICAL LABORATORIES LTD:  SUBSIDIARY SATSUMA PHARMACEUTICALS RECEIVED US FDA APPROVAL FOR ACUTE MIGRAINE TREATMENT ATZUMI (STS101)

Source text: ID:nTSqa810ca

Further company coverage: 2395.T

 (Reporting by Tokyo Newsroom)

 ((+81345201189;))